clinical
trial
bivalent
new
jersey
victoria
influenza
vaccine
high
risk
child
various
dos
two
whole
virus
one
split
product
bivalent
influenza
new
jersey
victoria
vaccine
administered
child
aged
six
year
statistically
significant
difference
either
reactivity
humoral
antibody
response
among
child
seven
chronic
disease
category
healthy
child
whole
virus
vaccine
associated
unacceptably
high
rate
reaction
given
sufficiently
antigenic
initial
dos
relatively
nonreactive
used
booster
immunization
split
product
vaccine
reactive
placebo
vaccine
preparation
induced
adequate
seroconversion
rate
protective
titer
antibody
victoria
virus
one
dose
new
jersey
virus
two
dos
